Is there a maximal effect of tranexamic acid in patients undergoing total knee arthroplasty? A randomized controlled trial

Yiting Lei1,2 | Jinwei Xie2 | Qiang Huang2 | Fuxing Pei2

1 Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China
2 Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, People’s Republic of China

Correspondence
Fuxing Pei, Department of Orthopedics, West China Hospital, Sichuan University, 37# Wainan Guoxue Road, Chengdu 610041, People’s Republic of China.
Email: peifux@126.com

Funding information
National Health and Family Planning Commission of the People’s Republic of China (CN) program

Abstract
The optimal dosing regimen of tranexamic acid (TXA) has not been determined in total knee arthroplasty (TKA). In this study, patients were randomized to receive a high initial-dose (60 mg/kg) TXA before incision, followed by five doses 3, 6, 12, 18, and 24 hours later (A), or three doses 3, 12, and 24 hours later (B), or a single dose 3 hours later (C). The primary outcome was perioperative blood loss. Other outcomes such as, hemoglobin level, transfusion, the levels of fibrinogen degradation products (FDP), D-dimer, C-reactive protein (CRP) and interleukin-6 (IL-6), coagulation parameters, and adverse events were also compared. The results showed that individuals in Groups A and B had reduced total and hidden blood loss (HBL), lower FDP, D-dimer, CRP, and IL-6 levels than in Group C. Such differences were also detected in HBL between Groups A and B. No differences were observed in other outcomes between Groups A and B. No differences were observed in coagulation parameters and adverse events among the three groups. In conclusion, a high initial-dose (60 mg/kg) TXA before TKA followed by three doses can be sufficient to achieve maximal effects on total blood loss, fibrinolysis, and inflammation.

KEYWORDS
blood loss, fibrinolysis, inflammation, total knee arthroplasty, tranexamic acid

1 INTRODUCTION

Total knee arthroplasty (TKA) is viewed as the best surgical approach to treat severe knee osteoarthritis and other knee diseases. However, surgical trauma is always accompanied by significant hyperfibrinolysis, which can lead to considerable blood loss and rising demand for blood transfusions. Although blood transfusion is a common procedure and generally safe, it still has a potential risk of morbidity and mortality. Therefore, various methods of blood conservation have been studied, including applying antifibrinolytic drugs.

Tranexamic acid (TXA) is an antifibrinolytic drug that promotes a reduction in fibrinolysis. Numerous studies have demonstrated a reduction in perioperative bleeding in patients who received TXA. Nevertheless, the...
optimal dosage of TXA in TKA is still undetermined. It is reported that multiple-dose regimen is superior to single-dose regimen, and a preoperative dose followed by a postoperative dose could be the least amount of dosage to effectively reduce blood loss. Our preceding research has been conducted to compare different loading dosages, which proved the effectiveness of a high initial dose (60 mg/kg) TXA on blood loss, fibrinolysis, and inflammatory response. The results were encouraging, but it is still unclear whether the use of a high initial dose TXA can reduce the maintenance dosage, since a high loading dose tends to maintain an effective concentration for a longer period. Therefore, the objective of our prospective, randomized, double-blind trial was to explore the optimal dosing regimen of TXA in TKA. We hypothesized that with a high initial dose (60 mg/kg) TXA, less maintenance doses could be sufficient to achieve maximal effects on blood loss, fibrinolysis, and inflammation.

2 METHODS

2.1 Study design

The trial protocol was approved by the ethics committee (2017-128) in accordance with the principles of the Helsinki Declarations. The trial has been registered prior to initiation (ChiCTR1800016640). All patients signed the written informed consent.

2.2 Patient cohort

From October 2018 to August 2019, we enrolled patients who had symptomatic, radiologically confirmed knee osteoarthritis and were scheduled for TKA in our medical center. Individuals were excluded if they had a history of pulmonary embolism (PE) or thromboembolic disease, an acquired or congenital coagulopathy, the current use of anticoagulant agents, renal or hepatic impairment, and allergy to TXA. Preoperative comorbidities were assessed after admission. Preoperative blood pressure was controlled below 140/90 mm Hg.

In total, there were 96 participants randomized to one of three groups. All patients received a high initial dose (60 mg/kg) TXA prior to operation. After the first administration, Group A received another five doses of 1 g TXA 3, 6, 12, 18, and 24 hours later; Group B received another three doses of 1 g TXA 3, 12, and 24 hours later; and Group C received another one dose of 2 g TXA 3 hours later.

2.3 Surgical procedures

All the surgical procedures were conducted by the same medical team under general anesthesia. Controlled hypotensive anesthesia (BP <100/60 mm Hg) was maintained during procedure. All the total knee prostheses were posterior stabilized cemented implants (PFC sigma). Drainage and tourniquet were not applied in any patients. To assess the volume of intraoperative blood loss (IBL), we meticulously recorded the weight of the gauze with blood. In addition, the amount of fluid collected in the aspirator was also recorded.

2.4 Postoperative care protocol

In our medical institution, all recruited patients were managed with the use of the same thromboprophylaxis protocol. Enoxaparin (Clexane; Sanofi-Aventis, Paris, France), 2000 IU/day, was started 6 hours after TKA. Our protocol for routine discharge from the hospital was on the third day after surgery. After discharge, rivaroxaban (Xarelto, Bayer, Leverkusen, Germany) was given orally in a dose of 10 mg once daily for 10 days. Each patient was screened with clinical symptoms and physical examination to ensure no deep venous thrombosis was present. PE was investigated by clinical features. Patient with clinically suspected PE would receive a contrast-enhanced chest computed tomography (CT) scan immediately. Doppler ultrasound was performed on the third postoperative day and repeated at 14 days and 90 days after surgery to detect venous thrombosis of lower extremities.

In our medical institution, the threshold for blood transfusion was as follows: (a) the hemoglobin level was equal to or less than 7 g/dL; (b) the hemoglobin level was in the range of 7-10 g/dL, accompanied by intolerable symptom of anemia (rapid heartbeat, lightheadedness, polypnea, or reduced exercise tolerance).

2.5 Outcome assessments

The relevant demographic and operative details were collected for comparisons. The patient’s blood volume, total blood loss (TBL), IBL, and hidden blood loss (HBL) were assessed as previously described.

Fibrinolysis factors were tested preoperatively and 1, 2, and 3 days after TKA. Inflammatory components, activated partial thromboplastin time (APTT), prothrombin time (PT), platelet count, and thrombelastography (TEG) were tested preoperatively and 1, 2, 3, and 14 days after TKA. TEG is a global assay of hemostasis, which has been shown to reflect the variation of coagulability. In this
TABLE 1 Demographic data of the patients receiving unilateral TKA

| Demographic Group | Group A (n = 32) | Group B (n = 32) | Group C (n = 32) | P value |
|-------------------|-----------------|-----------------|-----------------|---------|
| Age (year)        | 66.63 ± 6.70    | 65.25 ± 7.18    | 69.41 ± 7.49    | .065    |
| Gender (n)        |                 |                 |                 | .443    |
| Male              | 3               | 4               | 7               |         |
| Female            | 29              | 28              | 25              |         |
| Height (cm)       | 157.53 ± 4.23   | 154.78 ± 6.71   | 157.47 ± 7.49   | .143    |
| Weight (kg)       | 64.50 ± 9.82    | 61.25 ± 7.91    | 63.47 ± 8.75    | .329    |
| BMI (kg/m²)       | 25.95 ± 3.60    | 25.55 ± 2.83    | 25.56 ± 2.84    | .839    |
| Hypertension (n)  | 14              | 14              | 19              | .353    |
| Diabetes (n)      | 4               | 1               | 5               | .331    |
| ASA class 2 (n)   | 19              | 26              | 19              | .101    |
| 3 (n)             | 13              | 6               | 13              |         |
| HSS score         | 47.50 ± 6.13    | 46.91 ± 6.55    | 45.81 ± 6.46    | .564    |
| ROM (°)           | 99.84 ± 17.53   | 95.47 ± 11.66   | 97.66 ± 17.04   | .537    |
| Operated side     |                 |                 |                 | .272    |
| Left (n)          | 17              | 11              | 16              |         |
| Right (n)         | 15              | 21              | 16              |         |
| PBV (mL)          | 3750.09 ± 426.57| 3550.20 ± 424.19| 3695.11 ± 450.59| .169    |
| Operation time (min)| 72.38 ± 14.78  | 72.19 ± 15.56   | 77.53 ± 14.48   | .273    |
| INFV (mL)         | 410.94 ± 118.96 | 434.38 ± 151.04| 453.13 ± 162.61| .511    |

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; HSS, hospital for surgery; INFV, intraoperative intravenous fluid volume; PBV, patient blood volume; ROM, range of motion.

randomized controlled trial (RCT), blood was extracted into a citrate tube and left at room temperature for at least 15 minutes before testing. TEG was assessed using a RapidTEG Reagent (Hemostasis system, Braintree, Chicago, IL).

The level of anti-factor Xa activity (AFXa) is recommended to be monitored for dosage adjustment purposes in these patients receiving enoxaparin.18 In this RCT, blood was extracted into a CTAD tube, centrifuged at 2500 g for 18 minutes, and stored at −20 °C. Chromogenic substrate method was adopted for analysis of AFXa levels with the use of an Anti-Xa assay kit (Shanghai Zhenyuan Diagnostic Supplies Technology Co., Ltd., Shanghai, China). Enoxaparin was started 6 hours after TKA and continued once daily during the inpatient hospital stay. Based on the previous finding that the level of AFXa reached its peak at 4 hours after administration,18 we drew the blood one day before surgery, and repeated at 10 and 34 hours after TKA to assess AFXa. Transfusion rate and adverse events were recorded during hospitalization and 90-day follow-up period.

2.6 Data analysis

The sample size was calculated based on our pilot study with the use of PASS for Windows (version 11). It is shown that a sample size of 31 subjects per arm was required to detect a difference of 100 mL in TBL among groups with 90% power and P < .05. Anticipating an attrition rate of 22.5%, 120 patients had to be included.

All statistical analyses were performed with the use of SPSS for Windows (version 24). P values were judged significant if they were less than .05.

3 RESULTS

3.1 Baseline characteristics

From October 2018 to August 2019, there were 120 participants screened for participation in this trial. Among them, 13 were ineligible, 5 refused to consent, 4 dropped out, and 2 were lost to follow-up. Eventually, 96 patients were involved in the final analysis. Baseline characteristics were similar among groups (Table 1).

3.2 Perioperative blood loss and transfusion

The TBL, HBL, and maximum hemoglobin (Hb) drop in Groups A (P < .001, < .001, < .001) and B (P < .001, < .001,
TABLE 2  Postoperative blood loss and transfusion

|                 | Group A (n = 32) | Group B (n = 32) | Group C (n = 32) | P value | P1 | P2 | P3 |
|-----------------|------------------|------------------|------------------|---------|----|----|----|
| TBL (mL)        | 478.60 ± 169.43  | 583.97 ± 162.87  | 862.82 ± 222.97  | .000    | .068 | .000 | .000 |
| IBL (mL)        | 77.81 ± 19.13    | 71.88 ± 17.12    | 79.06 ± 16.14    | .220    | .368 | .956 | .233 |
| HBL (mL)        | 400.79 ± 171.69  | 512.10 ± 157.64  | 783.76 ± 222.97  | .000    | .049 | .000 | .000 |
| Max Hb drop     | 17.63 ± 7.15     | 22.13 ± 5.84     | 29.72 ± 14.29    | .000    | .165 | .000 | .007 |
| Transfusion (n) | 0                | 0                | 1                | 1.000   | 1.000 | 1.000 | 1.000 |

P, P value of group A vs B vs C; P1, P value of group A vs B; P2, P value of group A vs C; P3, P value of group B vs C.

Abbreviations: HBL, hidden blood loss; IBL, intraoperative blood loss; Max Hb drop, maximum hemoglobin drop; TBL, total blood loss.

3.3  Fibrinolysis parameters

As shown in Figure 1A,B, the levels of FDP on POD 1, 2, and 3 were significantly lower in Groups A (P = .007, .009, P < .001) and B (P = .030, .046, .023) compared to Group C. Such differences were also detected in HBL between Groups A and B (P = .049). However, no differences were found between Groups A and B in terms of TBL and maximum Hb drop (P = .068, .165). Furthermore, there were no significant differences in IBL and transfusion rate among the three groups (Table 2).

3.4  Inflammation markers

As shown in Figure 1C,D, significantly lower C-reactive protein (CRP) levels were detected in Groups A (P = .002, .006, P < .001) and B (P = .016, .034, .009) on POD 1, 2, and 3 compared to Group C. In addition, the interleukin-6
(IL-6) levels in Groups A ($P = .007, .004, .023$) and B ($P = .029, .009, .037$) were significantly lower than those in Group C on POD 1, 2, and 3. The levels of CRP and IL-6 were similar between Groups A and B.

### 3.5 Coagulation parameters and complications

No differences were found among the three groups in terms of postoperative APTT, PT, platelet count, r-TEG results, or AFXa (Figures 2 and 3, Table 3). Furthermore, the results of APTT, PT, platelet count, and r-TEG were within the normal range, and the results of AFXa were within the recommended prophylactic range. No significant differences were observed in thrombotic events among the three groups within 90 days (Table 3). No treatment-related complications such as PE, seizure, or cerebrovascular events occurred during hospitalization or 90-day follow-up period.

### 4 DISCUSSION

TKA is known to be an efficacious treatment modality for severe knee arthritis. However, surgical trauma that induces both the coagulation cascade and fibrinolysis can lead to significant blood loss. Accordingly, the focus of recent clinical studies has involved the use of antifibrinolytics. TXA is an antifibrinolytic drug that can not only noncompetitively inhibit plasmin but also competitively inhibit the lysine binding site. Although numerous studies have proved the efficacy of TXA, the reports regarding the optimal protocol of TXA in TKA are conflicting. As a cascade process, fibrinolytic activation is most easily controlled at its early phase. Therefore, the preoperative dose has been regarded as the most crucial dose. It has been suggested that TXA at doses more than 61 mg/kg may raise the risk of seizure, indicating that a dosage of 60 mg/kg might be the maximum safe dose. Our published study has demonstrated the superior efficacy of a high initial dose TXA (60 mg/kg) followed by five postoperative doses. However, the optimal postoperative TXA regimen still remains unclear. It is reported that it could be beneficial to maintain antifibrinolytic treatment in the postoperative period, and at least two perioperative doses could be required to be effective. Hourlier et al indicated that a higher loading dose could maintain an effective concentration for a longer period, which may explain why the previous works failed to detect the efficacy of single low-dose administration. Based on the above studies, we speculate that a high initial dose (60 mg/kg) TXA could reduce the volume of usage and the frequency of drug administration after TKA.

To our knowledge, this is the first attempt to explore the optimum postoperative TXA regimen to maximize the hemostatic effects and minimize the side effects with a high initial dose (60 mg/kg) TXA. With the same preoperative protocol, patients in our study were treated with another five doses of TXA (six-dose regimen), or another three doses of TXA (four-dose regimen), or another one dose of TXA (two-dose regimen). The main finding of this present study is that four-dose regimen can be sufficient to achieve a maximal effect on fibrinolysis, which could play a role in reducing TKA-associated blood loss. The level of FDP and D-dimer was tested to evaluate fibrinolysis. Individuals in two-dose group had higher FDP and D-dimer levels than those in four-dose and six-dose groups. Besides, the four-dose and six-dose regimens significantly reduced TBL, HBL, and maximum hemoglobin drop as compared with the two-dose regimen. Since fibrinolysis remains at a high level for 18-24 hours after TKA, repeated doses up to 24 hours could be more effective in inhibiting postoperative fibrinolysis, which could explain the differences between the two-dose regimen and the four- and six-dose regimens. Interestingly, no differences were observed between the four- and six-dose regimens in terms of blood-saving and antifibrinolytic efficacy. The results confirmed our hypothesis that a high loading dose could prolong the maintenance dosage intervals and reduce postoperative dosage.
Perioperative TEG analysis in patients undergoing TKA. TEG is a global assay of hemostasis which has been shown to reflect the variation of coagulability. TEG parameters mainly include TEG ACT (A), R(B), K(C), α-angle (D), MA (E), EPL (F), LY30 (G), and G (H). TEG ACT, thromboelastography-generated activated clotting time; R, perioperative reaction time; K, kinetics; α-angle, alpha-angle; MA, maximum amplitude; EPL, estimate percent lysis; LY30, lysis rate at 30 minutes; Pre-OP, preoperative; POD, postoperative.

Surgical stress elicited by TKA may increase the release of inflammatory components and may have negative influence on postoperative recovery. Despite various studies proving the efficacy of TXA with single or multiple boluses on fibrinolysis, no consensus has been reached on its anti-inflammatory properties. Previous studies showed that plasminogen could bind to inflammatory cells like monocytes, macrophages, and neutrophils, and D-dimer could raise the level of biologically active cytokines. Thus, it is logical to assume that there might be a cross-talk between fibrinolysis and inflammation, and TXA may have an anti-inflammatory effect through its inhibition of plasmin formation. In this present study, the level of CRP and IL-6 was measured to show the...
inflammatory status.\textsuperscript{38} We found significantly higher concentrations of CRP and IL-6 in the two-dose group than in the four- and six-dose groups. As expected, no difference was found between the four- and six-dose regimens, which was in accordance with difference in fibrinolysis parameters. Our results might provide an indirect support for the correlation between TXA and inflammation, and suggest that four-dose regimen can be sufficient to achieve a maximal effect on anti-inflammation.

It has been reported that the effect of anticoagulant therapy might be weakened by some hemostatic agents.\textsuperscript{39–41} Nevertheless, relatively little knowledge is available related to the correlation between TXA and anticoagulant drug. Honda et al and Levy et al used PT to assess the effect of TXA on edoxaban and rivaroxaban, and found that TXA failed to decrease the effects of anticoagulant therapy.\textsuperscript{42,43} However, the results of PT assays could be influenced by some extraneous factors, and anti-Xa assay could be less impacted by variability.\textsuperscript{44,45} To our knowledge, this is the first study based on AFXa, APTT, and PT to assess the influence of different postoperative TXA regimens with a high initial dose TXA on the effects of enoxaparin. No significant differences were observed among the three groups in terms of AFXa, APTT, and PT, and the results of APTT and PT remained within their normal ranges. More importantly, the postoperative AFXa remained within the recommended prophylactic range (0.1–0.3 IU/mL),\textsuperscript{46} indicating that a high loading dose of TXA followed by different maintenance dosage has no influence on the anticoagulant effect.

Although previous studies on TXA and thrombosis failed to show any thrombogenic effect, little focus has been shifted to the safety of different postoperative TXA regimens with a high initial dose TXA.\textsuperscript{1,6,47–49} Besides, the majority of previous RCTs were conducted with conditions of relatively small sample size,\textsuperscript{1,2,5} and it is known that at least 2000 individuals per group would be required to find a difference in this low-incidence event.\textsuperscript{50} In addition to clinical features, we also used TEG, PT, APTT, and platelet count to evaluate the effect of TXA on coagulation and platelet function in this present study. No differences in these parameters were observed among the three groups, and all of them were in their normal ranges, providing a further confirmation with regard to the safety of TXA.

Several limitations should be noted when interpreting the results. First, the sample size of this present trial may not large enough to detect potential complications related to TXA. Besides, the study’s generalizability to surgical populations is limited, since we excluded the patients with preexisting coagulopathy. Last but not the least, this study mainly compared the hemostatic, antifibrinolytic, and anti-inflammatory effects of different postoperative TXA regimens, the effects on postoperative pain level and knee function were absent in this trial, which merit further investigation. Despite its limitations, it is a prospective RCT with consistent anesthesia protocol, surgical procedures, and perioperative care regimens.

\section{CONCLUSION}

In conclusion, a high initial dose (60 mg/kg) followed by three doses of 1 g TXA 3, 12, and 24 hours later has favorable effects on TBL, fibrinolysis, and inflammation in TKA. However, although this study suggested an optimal dosing regimen among the three regimens, there might exist a better regimen with different initial dose and maintenance doses. Further studies in large scales are still required to evaluate the benefit to risk ratio before final recommendations.

\section{ACKNOWLEDGMENTS}

We acknowledge the nursing staffs from Department of Orthopaedic Surgery, West China Hospital and the patients for their support during the study period.

\section{CONFLICT OF INTEREST}

The authors declare no conflict of interest.

\section{FUNDING INFORMATION}

National Health and Family Planning Commission of the People’s Republic of China (CN) program; Grant Number: 201302007.
ETHICAL APPROVAL
This trial was approved by the institutional review board (2017-128).

INFORMED CONSENT
Informed consent was obtained from all individual participants included in the study.

ORCID
Fuixing Pei https://orcid.org/0000-0003-0733-3433

REFERENCES
1. Xie J, Ma J, Yao H, et al. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial. *J Arthroplasty*. 2016;31(11):2458-2464.
2. Lei Y, Xie J, Xu B, et al. The efficacy and safety of multiple-dose intravenous tranexamic acid on blood loss following total knee arthroplasty: a randomized controlled trial. *Int Orthop*. 2017;41:2053-2059.
3. Liu KL, Chen IH, Wen SH. Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: a population-based study in Taiwan. *J Formos Med Assoc*. 2017;116(1):24-31.
4. Rineau E, Chaudet A, Chassier C, Bizot P, Lasocki S. Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study. *Transfusion*. 2016;56:673-681.
5. Xie J, Hu Q, Ma J, Huang Q, Pei F. Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss and the inflammatory response following enhanced-recovery primary total hip arthroplasty: a randomized clinical trial. *Bone Joint J*. 2017;99-B:1442-1449.
6. Morrison RJM, Tsang B, Fishley W, Harper I, Joseph JC, Reed MR. Dose optimisation of intravenous tranexamic acid for elective hip and knee arthroplasty: the effectiveness of a single preoperative dose. *Bone Joint Res*. 2017;6:499-505.
7. Maniari RN, Kumar G, Singh T, et al. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. *Clin Orthop Relat Res*. 2012;470:2605-2612.
8. Xie J, Hu Q, Huang Q, et al. Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis. *Thromb Res*. 2017;153:28-36.
9. Akgul T, Buget M, Salduz A, et al. Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: a prospective clinical study. *Acta Orthop Traumatol Turc*. 2016;50:429-431.
10. Whiting DR, Sierra RJ. Efficacy of combined use of intraarticular and intravenous tranexamic acid in total knee arthroplasty. *Ann Transl Med*. 2015;3:S39.
11. Lei Y-T, Xie J-W, Huang Q, Huang W, Pei F-X. The antifibrinolytic and anti-inflammatory effects of a high initial-dose tranexamic acid in total knee arthroplasty: a randomized controlled trial. *Int Orthop*. 2020;44:477-486.
12. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. *Surgery*. 1962;51:224-232.
13. Gross JB. Estimating allowable blood loss: corrected for dilution. *Anesthesiology*. 1983;58:277-280.
14. Kathriya R, Devanoorkar A, Jain H. Intra-operative hemorrhage: a review of literature. *J Med Diagn Meth*. 2013;02:06.
15. Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty: Correct management of blood loss should take hidden loss into account. *J Bone Joint Surg Br*. 2004;86:561-565.
16. Mallett SV, Cox DJ. Thrombelastography. *Br J Anaesth*. 1992;69:307-313.
17. Saloja N, Perry DJ. Thrombelastography. *Blood Coagul Fibrinolysis*. 2001;12:327-337.
18. Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. *Hematol Rep*. 2015;7:5844.
19. Iwai T, Tsuji S, Tomita T, et al. Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. *Int Orthop*. 2013;37:441-445.
20. Carabini LM, Moreland NC, Vealey RJ, et al. A randomized controlled trial of low-dose tranexamic acid versus placebo to reduce red blood cell transfusion during complex multilevel spine fusion surgery. *World Neurosurg*. 2018;110:e572-e579.
21. Huang GP, Jia XF, Xiang Z, et al. Tranexamic acid reduces hidden blood loss in patients undergoing total knee arthroplasty: a comparative study and meta-analysis. *Med Sci Monit*. 2016;22:797-802.
22. Lee SY, Chong S, Balasubramanian D, et al. What is the ideal route of administration of tranexamic acid in TKA? A randomized controlled trial. *Clin Orthop Relat Res*. 2017;475:1987-1996.
23. Dahuja A, Dahuja G, Jaswal V, et al. A prospective study on role of tranexamic acid in reducing postoperative blood loss in total knee arthroplasty and its effect on coagulation profile. *J Arthroplasty*. 2014;29:733-735.
24. Jain NP, Nisthane PP, Shah NA. Combined administration of systemic and topical tranexamic acid for total knee arthroplasty: can it be a better regimen and yet safe? A randomized controlled trial. *J Arthroplasty*. 2016;31:542-547.
25. Rajesparan K, Biant LC, Ahmad M, et al. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. *J Bone Joint Surg Br*. 2009;91:776-783.
26. Bhat A, Bhowmik DM, Vibha D, et al. Tranexamic acid overdose-induced generalized seizure in renal failure. *Saudi J Kidney Dis Transpl*. 2014;25:130-132.
27. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. *Anesth Analg*. 2010;110:350-353.
28. Hourlier H, Reina N, Fennema P. Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial. *Arch Orthop Trauma Surg*. 2015;135:465-471.
29. Blanie A, Bellamy L, Rhayem Y, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. *Thromb Res*. 2013;133:e6-e11.
30. Huang Z, Xie X, Li L, et al. Intravenous and topical tranexamic acid alone are superior to tourniquet use for primary total knee arthroplasty: a prospective, randomized controlled trial. *J Bone Joint Surg Am*. 2017;99:2053-2061.
31. Jules-Elysee KM, Lippnitsky JY, Patel N, et al. Use of low-dose steroids in decreasing cytokine release during bilateral total knee replacement. *Reg Anesth Pain Med*. 2011;36:36-40.
32. Bautmans I, Njemini R, De Backer J, et al. Surgery-induced inflammation in relation to age, muscle endurance, and self-perceived fatigue. *J Gerontol A Biol Sci Med Sci*. 2010;65:266-273.
33. Jimenez JJ, Iribarren JL, Lorente L, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. *Crit Care*. 2007;11:R117.
34. Robson SC, Shephard EG, Kirsch RE. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. *Br J Haematol*. 1994;86:322-326.
35. Godier A, Roberts I, Hunt BJ. Tranexamic acid: less bleeding and less thrombosis?. *Crit Care*. 2012;16:135.
36. Jimenez JJ, Iribarren JL, Brouard M, et al. Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. *J Cardiothorac Surg*. 2011;6:138.
37. Robertshaw HJ. An anti-inflammatory role for tranexamic acid in cardiac surgery? *Crit Care*. 2008;12:105.
38. Wasko MK, Bobecka-Wesolowska K, Tomasiuk R, et al. Measurement of the inflammatory response in the early postoperative period after hip and knee arthroplasty. *Clin Chem Lab Med*. 2015;53:1785-1792.
39. Toshio F, Yuko H, Chikako K, et al. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. *Thromb Haemost*. 2012;107:253-259.
40. Hamim Z, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. *Circulation*. 2015;131:82-90.
41. Eva H, Franz K, Wilfried K, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. *Anesthesiology*. 2015;122:387-398.
42. Levy JH, Moore KT, Neal MD, et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. *J Thromb Haemost*. 2018;16:54-64.
43. Honda Y, Furugohri T, Morishima Y. Tranexamic acid failed to reverse the anticoagulant effect and bleeding by an oral direct factor Xa inhibitor edoxaban. *Pharmacology*. 2018;101:92-95.
44. Chen BY, Zhaoqing W, Charles F, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. *Thromb Haemost*. 2010;104:1263-1271.
45. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus anti-factor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. *Ann Pharmacother*. 2011;45:861-868.
46. Helviz Y, Dzigivker I, Raveh-Brawer D, et al. Anti-factor Xa activity of prophylactic enoxaparin regimens in critically ill patients. *Isr Med Assoc J*. 2016;18:108-113.
47. Kundu R, Das A, Basunia SR, et al. Does a single loading dose of tranexamic acid reduce perioperative blood loss and transfusion requirements after total knee replacement surgery? A randomized, controlled trial. *J Nat Sci Biol Med*. 2015;6:94-99.
48. Gillette BP, DeSimone LJ, Trousdale RT, et al. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. *Clin Orthop Relat Res*. 2013;471:150-154.
49. Kim YH, Park JW, Kim JS, et al. Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian population? *Arch Orthop Trauma Surg*. 2018;138:83-89.
50. Xie J, Ma J, Kang P, et al. Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. *Thromb Res*. 2015;136:234-238.

**How to cite this article:** Lei Y, Xie J, Huang Q, Pei F. Is there a maximal effect of tranexamic acid in patients undergoing total knee arthroplasty? A randomized controlled trial. *MedComm*. 2020;1:219–227. https://doi.org/10.1002/mco2.23